Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study
November 22, 2023 04:20 ET
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, Nov. 22, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Oncology Drug Discovery & Development Market-...
Celsion Corporation Announces Pricing of $10 Million Underwritten Offering of Common Stock
June 22, 2020 15:00 ET
|
Celsion CORP
Lawrenceville, NJ, June 22, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to...
Provectus Names Harold Schmitz, PhD to Company's Scientific Advisory Board
September 11, 2019 07:00 ET
|
Provectus Biopharmaceuticals Inc.
Dr. Schmitz, General Partner of The March Fund and former Chief Science Officer of Mars, Incorporated is Provectus’ inaugural Scientific Advisory Board member KNOXVILLE, TN, Sept. 11, 2019 (GLOBE...
Celsion Corporation Announces Issuance of New Patent for ThermoDox®
April 17, 2019 08:00 ET
|
Celsion CORP
Represents a Significant Advance for Celsion’s Life Cycle Management Program for ThermoDox® Establishing Bioequivalence Will Extend Market Exclusivity to 2033 LAWRENCEVILLE, N.J,...
PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA
February 12, 2019 07:30 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to small...